MedTrace Logo

Study on Using Radiofrequency to Treat Moderate to Severe Acne

NCT06315166 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-02-19

No results posted yet for this study

Summary

Evaluation of the safety and efficacy of fractional radiofrequency for the treatment of moderate to severe acne vulgaris.

Conditions

  • Moderate to Severe Acne Vulgaris

Interventions

DEVICE

triLift/Legend Pro+ Fractional RF System

The triLift/Legend Pro+ Fractional investigational device is intended for the treatment of acne vulgaris when using Fractional RF energy.

Sponsors & Collaborators

  • Lumenis Be Ltd.

    collaborator INDUSTRY

  • Pollogen

    lead INDUSTRY

Principal Investigators

  • Yuri Vinshtok · Pollogen Ltd.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-23
Primary Completion
2026-12-31
Completion
2027-12-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06315166 on ClinicalTrials.gov